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The incremental benefits of obtaining higher levels of skin clearance for patients with psoriasis have been established across several patient reported outcomes (PROs). Patients who obtain clear or almost clear skin are more likely to report no impact of psoriasis on health-related quality of life (HRQoL) and other symptom measures. [1] [2] [3] While the benefits of obtaining higher skin clearance have been reported with different therapeutic agents, the question of whether the benefits of such high levels of response may be offset by an increased risk for adverse outcomes has not been fully explored with biologics. 4 In this study, improvements in HRQoL and psoriasis symptoms in patients with increased skin clearance were examined in relationship to adverse events (AEs) to determine whether higher levels of skin clearance were associated with greater risks for AEs. Data were obtained from two phase 3 trials of ixekizumab in patients with moderate-to-severe plaque psoriasis (UNCOVER-2 and UNCOVER-3). The primary study design and outcomes have been reported elsewhere.
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Efficacy on skin clearance was assessed using the Psoriasis Area Severity Index (PASI 
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This article is protected by copyright. All rights reserved. At Week 12, one third of patients had <75% PASI improvement from baseline and two thirds had PASI improvements evenly distributed across higher levels of skin improvement (Table 1 ). Most patients with PASI <75 were from the PBO (n=341, 37.6%) or ETN (n=380, 41.9%) groups, while most of the PASI100 patients were from the IXEQ4W (n=246, 41.8%) and IXEQ2W (n=293, 49.8%) groups.
At Week 12, greater PASI improvements were associated with significantly better PROs compared with lower PASI responses (Table 1) . Specifically, for itch NRS outcomes and DLQI (0,1), each incremental increase in PASI response was associated with significantly better PROs.
With regards to safety, the frequency of patients reporting ≥1 TEAE was significantly greater (p<0.008) with higher levels of skin improvement; however, significantly fewer patients with higher levels of skin improvement reported ≥1 TEAE that was severe (p=0.021) or discontinued due to AEs (p=0.038; Table 1 ). There were no statistical significant associations between skin improvements and infections or SAEs (Table 1 , Fig. 1 ). Among IXE-treated patients, there were no significant associations between skin improvements and TEAE or SAE rates (Q4W: TEAE p=0.818, SAE p=0.368, Q2W: TEAE p=0.099, SAE p=0.255).
The findings of the present study indicate that attaining near complete or complete resolution of psoriasis resulted in more beneficial PROs compared with patients who had lower levels of skin improvement. The increased benefits observed in patients with higher levels of improvement (i.e., PASI ≥90) suggest that, while PASI75 remains a clinically meaningful response to treatment, physicians should also recognise the benefits of attaining greater clearance with treatment. The
increased benefit of skin clearance resulted in clinically important and meaningful improvements in patients' lives that could be obtained within an acceptable safety profile. This conclusion should be considered within the context of study limitations for the short-term treatment period (i.e., a potential selection bias in PASI groupings, lack of power for detecting rare safety events, and the use of high-level safety outcomes). Future studies are needed to better understand associations between long-term skin improvement and long-term safety.
With novel biologic therapies being developed and approved for use in psoriasis, including IL-17 antagonists, physicians can now recommend treatments that provide the highest levels of skin improvements seen to date. While higher levels of efficacy associated with nonbiologic systemic therapies, such as methotrexate and ciclosporin, have been associated with higher risks for AEs and SAEs, 4 the present study provides additional evidence to support a paradigm shift when considering this issue in the context of biologic therapy.
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